Sameer S Kadri

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4512129/publications.pdf

Version: 2024-02-01

86 papers	4,265 citations	172386 29 h-index	118793 62 g-index
86 all docs	86 docs citations	86 times ranked	5435 citing authors

#	Article	IF	Citations
1	Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009-2014. JAMA - Journal of the American Medical Association, 2017, 318, 1241.	3.8	1,180
2	Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. Clinical Infectious Diseases, 2018, 67, 1803-1814.	2.9	234
3	Prevalence of Antibiotic-Resistant Pathogens in Culture-Proven Sepsis and Outcomes Associated With Inadequate and Broad-Spectrum Empiric Antibiotic Use. JAMA Network Open, 2020, 3, e202899.	2.8	190
4	Estimating Ten-Year Trends in Septic ShockÂIncidence and Mortality in United States Academic Medical CentersÂUsing Clinical Data. Chest, 2017, 151, 278-285.	0.4	172
5	Uptake and Accuracy of the Diagnosis Code for COVID-19 Among US Hospitalizations. JAMA - Journal of the American Medical Association, 2020, 324, 2553.	3.8	139
6	Diagnosing sepsis is subjective and highly variable: a survey of intensivists using case vignettes. Critical Care, 2016, 20, 89.	2.5	134
7	Association Between Caseload Surge and COVID-19 Survival in 558 U.S. Hospitals, March to August 2020. Annals of Internal Medicine, 2021, 174, 1240-1251.	2.0	133
8	Evaluation and Management of Necrotizing Soft Tissue Infections. Infectious Disease Clinics of North America, 2017, 31, 497-511.	1.9	131
9	Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals. Lancet Infectious Diseases, The, 2021, 21, 241-251.	4.6	130
10	Key Takeaways From the U.S. CDCâ€™s 2019 Antibiotic Resistance Threats Report for Frontline Providers. Critical Care Medicine, 2020, 48, 939-945.	0.4	123
11	Does Obesity Protect Against Death in Sepsis? A Retrospective Cohort Study of 55,038 Adult Patients*. Critical Care Medicine, 2019, 47, 643-650.	0.4	107
12	Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure. Clinical Infectious Diseases, 2021, 72, 541-552.	2.9	103
13	Sepsis Surveillance Using Adult Sepsis Events Simplified eSOFA Criteria Versus Sepsis-3 Sequential Organ Failure Assessment Criteria*. Critical Care Medicine, 2019, 47, 307-314.	0.4	85
14	Procalcitonin-Guided Antibiotic Discontinuation and Mortality in Critically Ill Adults. Chest, 2019, 155, 1109-1118.	0.4	82
15	Geographic Distribution of Nontuberculous Mycobacterial Species Identified among Clinical Isolates in the United States, 2009â€“2013. Annals of the American Thoracic Society, 2017, 14, 1655-1661.	1.5	75
16	Epidemiology of Hospital-Onset Versus Community-Onset Sepsis in U.S. Hospitals and Association With Mortality: A Retrospective Analysis Using Electronic Clinical Data. Critical Care Medicine, 2019, 47, 1169-1176.	0.4	75
17	Late Conditions Diagnosed 1â€“4 Months Following an Initial Coronavirus Disease 2019 (COVID-19) Encounter: A Matched-Cohort Study Using Inpatient and Outpatient Administrative Dataâ€”United States, 1 Marchâ€“30 June 2020. Clinical Infectious Diseases, 2021, 73, S5-S16.	2.9	71
18	Objective Sepsis Surveillance Using Electronic Clinical Data. Infection Control and Hospital Epidemiology, 2016, 37, 163-171.	1.0	66

#	Article	IF	Citations
19	Impact of Intravenous Immunoglobulin on Survival in Necrotizing Fasciitis with Vasopressor-dependent Shock: A Propensity-Score Matched Analysis from 130 US Hospitals. Clinical Infectious Diseases, 2017, 64, ciw871.	2.9	65
20	Effect of Procalcitonin Testing on Health-care Utilization and Costs in Critically Ill Patients in the United States. Chest, 2017, 151, 23-33.	0.4	55
21	Invasive Candidiasis Species Distribution and Trends, United States, 2009â€“2017. Journal of Infectious Diseases, 2021, 223, 1295-1302.	1.9	51
22	Role of granulocyte transfusions in invasive fusariosis: systematic review and singleâ€€center experience. Transfusion, 2015, 55, 2076-2085.	0.8	49
23	External Validation of Difficult-to-Treat Resistance Prevalence and Mortality Risk in Gram-Negative Bloodstream Infection Using Electronic Health Record Data From 140 US Hospitals. Open Forum Infectious Diseases, 2019, 6, ofz110.	0.4	45
24	Effectiveness of adjunctive clindamycin in Î²-lactam antibiotic-treated patients with invasive Î²-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study. Lancet Infectious Diseases, The, 2021, 21, 697-710.	4.6	45
25	Granulocyte transfusions in the management of invasive fungal infections. British Journal of Haematology, 2017, 177, 357-374.	1.2	44
26	Variation in Identifying Sepsis and Organ Dysfunction Using Administrative Versus Electronic Clinical Data and Impact on Hospital Outcome Comparisons*. Critical Care Medicine, 2019, 47, 493-500.	0.4	42
27	Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole. Current Fungal Infection Reports, 2015, 9, 74-87.	0.9	38
28	Epidemiology of Quick Sequential Organ Failure Assessment Criteria in Undifferentiated Patients and Association With Suspected Infection and Sepsis. Chest, 2019, 156, 289-297.	0.4	38
29	The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. Journal of Critical Care, 2020, 58, 58-64.	1.0	31
30	Mass Critical Care Surge Response During COVID-19. Chest, 2022, 161, 429-447.	0.4	31
31	Association Between Implementation of the Severe Sepsis and Septic Shock Early Management Bundle Performance Measure and Outcomes in Patients With Suspected Sepsis in US Hospitals. JAMA Network Open, 2021, 4, e2138596.	2.8	28
32	Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study. Lancet Infectious Diseases, The, 2020, 20, 1172-1181.	4.6	25
33	Risk Factors for In-Hospital Mortality in Smoke Inhalation-Associated Acute Lung Injury. Chest, 2016, 150, 1260-1268.	0.4	24
34	Extrapulmonary Nontuberculous Mycobacteria Infections in Hospitalized Patients, United States, 2009â€“2014. Emerging Infectious Diseases, 2021, 27, 845-852.	2.0	24
35	Suspected Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Reinfections: Incidence, Predictors, and Healthcare Use Among Patients at 238 US Healthcare Facilities, 1 June 2020 to 28 February 2021. Clinical Infectious Diseases, 2022, 74, 1489-1492.	2.9	24
36	Antimicrobial Treatment Duration in Sepsis and Serious Infections. Journal of Infectious Diseases, 2020, 222, S142-S155.	1.9	23

#	Article	IF	Citations
37	Pharmacoepidemiology of Ceftazidime-Avibactam Use: A Retrospective Cohort Analysis of 210 US Hospitals. Clinical Infectious Diseases, 2021, 72, 611-621.	2.9	23
38	Trimethoprim-Sulfamethoxazole Versus Levofloxacin for Stenotrophomonas maltophilia Infections: A Retrospective Comparative Effectiveness Study of Electronic Health Records from 154 US Hospitals. Open Forum Infectious Diseases, 2022, 9, ofab644.	0.4	22
39	High-Frequency Ventilation Modalities as Salvage Therapy for Smoke Inhalationâ€“Associated Acute Lung Injury: A Systematic Review. Journal of Intensive Care Medicine, 2018, 33, 335-345.	1.3	21
40	Critical Care Medicine and Infectious Diseases: An Emerging Combined Subspecialty in the United States: Figure 1.. Clinical Infectious Diseases, 2015, 61, 609-614.	2.9	19
41	Tracking Colistin-Treated Patients to Monitor the Incidence and Outcome of Carbapenem-Resistant Gram-Negative Infections. Clinical Infectious Diseases, 2015, 60, 79-87.	2.9	18
42	Potential Implications of SARS-CoV-2 Delta Variant Surges for Rural Areas and Hospitals. JAMA - Journal of the American Medical Association, 2021, 326, 1003.	3.8	17
43	IDSA guidance and ESCMID guidelines: complementary approaches toward a care standard for MDR Gram-negative infections. Clinical Microbiology and Infection, 2022, 28, 465-469.	2.8	16
44	Prevalence and Outcomes of Previously Healthy Adults Among Patients Hospitalized With Community-Onset Sepsis. Chest, 2022, 162, 101-110.	0.4	15
45	Racial difference in cardiovascular outcomes following percutaneous coronary intervention in a public health service patient population. Journal of Invasive Cardiology, 2010, 22, 168-73.	0.4	15
46	Reply to Burnham and Vazquez Guillamet. Clinical Infectious Diseases, 2017, 64, ciw790.	2.9	14
47	Epidemiology, Outcomes, and Trends of Patients With Sepsis and Opioid-Related Hospitalizations in U.S. Hospitals*. Critical Care Medicine, 2021, 49, 2102-2111.	0.4	13
48	Difficult-to-Treat Antibiotic-Resistant Gram-Negative Pathogens in the Intensive Care Unit: Epidemiology, Outcomes, and Treatment. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 419-434.	0.8	11
49	Mycobacterial Testing Trends, United States, 2009â€“20151. Emerging Infectious Diseases, 2020, 26, 2243-2246.	2.0	11
50	Dwindling Utilization of Central Venous Catheter Tip Cultures: An Analysis of Sampling Trends and Clinical Utility at 128 US Hospitals, 2009â€“2014. Clinical Infectious Diseases, 2019, 69, 1797-1800.	2.9	10
51	U.S. Efforts to Curb Antibiotic Resistance â€” Are We Saving Lives?. New England Journal of Medicine, 2020, 383, 806-808.	13.9	10
52	24: IMPACT OF PENALTIES FOR CENTRAL LINE-ASSOCIATED BLOODSTREAM INFECTIONS ON BLOOD CULTURE ORDERING. Critical Care Medicine, 2016, 44, 92-92.	0.4	9
53	Risk Adjustment for Sepsis Mortality to Facilitate Hospital Comparisons Using Centers for Disease Control and Preventionâ€™s Adult Sepsis Event Criteria and Routine Electronic Clinical Data. , 2019, 1, e0049.		9
54	Impact of Risk Adjustment Using Clinical vs Administrative Data on Hospital Sepsis Mortality Comparisons. Open Forum Infectious Diseases, 2020, 7, ofaa213.	0.4	9

#	Article	IF	Citations
55	Preintubation Sequential Organ Failure Assessment Score for Predicting COVID-19 Mortality: External Validation Using Electronic Health Record From 86 U.S. Healthcare Systems to Appraise Current Ventilator Triage Algorithms*. Critical Care Medicine, 2022, 50, 1051-1062.	0.4	9
56	Synergy, Salary, and Satisfaction: Benefits of Training in Critical Care Medicine and Infectious Diseases Gleaned From a National Pilot Survey of Dually Trained Physicians. Clinical Infectious Diseases, 2016, 63, 868-875.	2.9	8
57	Attributable mortality from extensively drug-resistant gram-negative infections using propensity-matched tracer antibiotic algorithms. American Journal of Infection Control, 2019, 47, 1040-1047.	1.1	8
58	Generalized chest CT and lab curves throughout the course of COVID-19. Scientific Reports, 2021, 11, 6940.	1.6	8
59	Prognostic significance of preprocedural troponin-I in patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention. Coronary Artery Disease, 2010, 21, 261-265.	0.3	6
60	Missing diagnoses of congenital cytomegalovirus infection in electronic health records for infants with laboratory-confirmed infection. Current Medical Research and Opinion, 2022, 38, 273-275.	0.9	6
61	Real-World Inpatient Use of Medications Repurposed for Coronavirus Disease 2019 in United States Hospitals, Marchâ€“May 2020. Open Forum Infectious Diseases, 2021, 8, ofaa616.	0.4	5
62	Central Venous Catheter Failures. Critical Care Medicine, 2018, 46, 2054-2056.	0.4	4
63	Prevalence and Clinical Characteristics of Patients With Sepsis Discharge Diagnosis Codes and Short Lengths of Stay in U.S. Hospitals. , 2021, 3, e0373.		4
64	Frequency and Risk of Emergency Medical Service Interhospital Transportation of Patients With Acute Lower Respiratory Tract Illness During the COVID-19 Pandemic in the US. JAMA - Journal of the American Medical Association, 2022, 327, 874.	3.8	4
65	The Epidemiology of Procalcitonin Use in United States Hospitals. Open Forum Infectious Diseases, 2016, 3, .	0.4	3
66	Body-mass index and all-cause mortality. Lancet, The, 2017, 389, 2284.	6.3	3
67	On the Interface of Infectious Diseases and Critical Care Medicine. Infectious Disease Clinics of North America, 2017, 31, xiii-xiv.	1.9	3
68	Recognizing the Unique Role of Critical Care Providers in Confronting Antimicrobial Resistance. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 560-562.	2.5	3
69	A Reappraisal of Streptococcal Urinary Antigen Testing for Antibiotic Stewardship. Clinical Infectious Diseases, 2020, 71, 1435-1437.	2.9	3
70	Can financial rewards for stewardship in primary care curb antibiotic resistance?. Lancet Infectious Diseases, The, 2021, 21, 1618-1620.	4.6	3
71	Trends in clinical severity of hospitalized patients with COVID-19, Premier Hospital Dataset, April 2020 â€“ April 2021. Open Forum Infectious Diseases, 2022, 9, ofab599.	0.4	3
72	Reply to Raoult and Rolain, and to Echols and Tillotson. Clinical Infectious Diseases, 2019, 69, 1642-1644.	2.9	2

#	Article	IF	Citations
73	56: EPIDEMIOLOGY, OUTCOMES, AND TRENDS OF SEPSIS IN PATIENTS WITH OPIOID USE DISORDERS IN U.S. HOSPITALS. Critical Care Medicine, 2020, 48, 28-28.	0.4	2
74	Adjunctive clindamycin therapy in invasive Î²-haemolytic streptococcal infections â€“ Authors' reply. Lancet Infectious Diseases, The, 2021, 21, 762-763.	4.6	2
75	15: IMPACT OF CENTRAL VENOUS CATHETERS ON FIVE-YEAR TRENDS IN ICU BACTEREMIA AT 63 HOSPITALS. Critical Care Medicine, 2018, 46, 8-8.	0.4	1
76	43: DIFFICULT-TO-TREAT RESISTANCE IN GRAM-NEGATIVE BACTEREMIA AMONG ICU INPATIENTS AT 162â€‰U.S. HOSPITALS. Critical Care Medicine, 2018, 46, 22-22.	0.4	1
77	Identifying Septic Shock Hospitalizations Using Supervised Machine Learning Classification Algorithms with Electronic Clinical Data. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
78	Species Distribution of Invasive Candidiasis, 2009â€“2013, United States. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
79	Response. Chest, 2017, 152, 219-220.	0.4	0
80	Impact of Procalcitonin (PCT)-Guided Antibiotic Therapy on Mortality in Critically Ill Patients: AÂSystematic Review and Meta-Analysis of 18 Randomized Controlled Trials. Open Forum Infectious Diseases, 2017, 4, S351-S351.	0.4	0
81	Epidemiology of Inappropriate Empiric Antibiotic Therapy for Bacteremia Based on Discordant In vitro Susceptibilities: Risk factors and Taxon-level Variation in Burden and Outcome in 156 US hospitals, 2000â€“2014. Open Forum Infectious Diseases, 2017, 4, S13-S14.	0.4	0
82	2089. Dwindling Utilization of Central Venous Catheter Tip Cultures: An Analysis of Sampling Trends and Clinical Utility at 128 U.S. Hospitals 2009â€“2014. Open Forum Infectious Diseases, 2018, 5, S611-S612.	0.4	0
83	1163. Impact of Difficult-to-Treat Resistance on Survival in Gram-Negative Bacteremia: A Risk-Adjusted Analysis Using Electronic Health Record-based Clinical Data From 140 US Hospitals. Open Forum Infectious Diseases, 2018, 5, S350-S350.	0.4	0
84	1624. Critical Care Medicine, 2019, 47, 787.	0.4	0
85	The Sepsis Proxy Pageant: Seeking Beauty in Imperfection*. Critical Care Medicine, 2020, 48, 1917-1919.	0.4	0
86	Population-Level Burden of Delayed or In Vitro Discordant Empiric Antibiotics Among Bacteremic Patients at US Hospitals. Infection Control and Hospital Epidemiology, 2020, 41, s44-s45.	1.0	0